Form 4: Arbutus Biopharma CEO Granted Stock Options

Lindsay Androski, President and CEO of Arbutus Biopharma, was granted stock options to purchase 310,422 common shares.

Summary

• On March 18, 2025, Lindsay Androski, the President and CEO of Arbutus Biopharma Corp, was granted stock options.
• These options allow Androski to purchase 310,422 common shares at an exercise price of $3.20 per share.
• The options vest over a four-year period, with 25% vesting on the first anniversary of the grant date.
• The remaining 75% vests in substantially equal monthly installments over the subsequent three years, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The granting of stock options is generally viewed positively as it aligns management's interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the biopharmaceutical industry.
• Companies like Gilead Sciences and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Arbutus Biopharma, ABUS, Lindsay Androski, CEO, equity compensation, Form 4